Thomas Sécher, INSERM - Qepler Summits And Conferences

Thomas Sécher

Inserm - From science to health

Thomas is a research scientist in the field of mucosal immunology and therapeutics. He is particularly concerned about infectious diseases and the way we can prevent them. Quickly realized the importance of the host-pathogen-environment triad in determining the outcome of infectious events and he was fascinated by the host-pathogen dualism and how their interactions dictate pathogenesis and subsequently modulate the efficacy of therapeutics. Studying this in more details has always been the driving force of my research.

Thomas owned a PhD in immunology/infectiology and have more than 10 years of experience in mucosal immunology and experimental disease models. After pursuing research projects at the CNRS (UMR 6218, Orléans, France) and INSERM (UMR1043, Toulouse, France), he joined the Research Center for Respiratory Diseases in Tours in 2016. His research interests are mainly focused on proof-of-concept for aerosol delivery of biotherapeutics and mainly therapeutic antibodies to treat respiratory tract infections.

Thomas (co-)authored more than 40 peer-reviewed publications, 1 patent and has given more than 20 oral presentations. He was a member of the scientific committee for the 7th (2019) and 9th (2021) AIS congress and actively serves as reviewer for Frontiers in Immunology, Frontiers in Microbiology, Gut and Plos One.

Related Sessions:

2nd Annual Inhaled
Drug Delivery Summit 2021

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 05 Aug 2021
  • Virtual,
  • Pharma
Day 1: Thursday, 05 August 2021
CASE STUDY: Inhalation of therapeutics to fight respiratory tract infections
  • Inhalation addresses drugs topically as an aerosol through the nose and/or mouth to its site of action in the respiratory tract. Actually, inhalation is the gold standard for the delivery of drugs with topical action to treat asthma, chronic obstructive respiratory disease (COPD) or cystic fibrosis (CF).
  • Inhalation provides a better therapeutic index for some drugs, often requires reduced dose as compared to other routes and is non-invasive, improving patient compliance and comfort.
  • Presently, most (topical) inhaled drugs are small molecules from different classes. Despite the obvious theoretical advantages of topical administration for therapeutics antibody (Ab) by inhalation, few of these benefits have yet materialized in the clinics.
  • This paucity highlights the complexity of developing inhaled antibodies and points out the persisting hurdles to overcome. A detailed understanding of the biology and pharmacology of inhaled Ab is required to ensure the successful transition from pre-clinical to clinical assessment.
View Details